Diels van den Dobbelsteen

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 215 citations

Pharmacy, Oncology, Pharmacology +16

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim H.A. Dokter, Ruud Ubink, Miranda van der Lee et al. · Molecular Cancer Therapeutics · 2014 · 163 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Sugammadex is cleared rapidly and primarily unchanged via renal excretion

Pierre Peeters, Paul Passier, Jean Smeets et al. · Biopharmaceutics & Drug Disposition · 2011 · 57 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Mary J. van Helden, Seline A. Zwarthoff, Roel J. Arends et al. · Journal for ImmunoTherapy of Cancer · 2023 · 19 citations · Full text

Medicine, Immunology, Oncology +16